GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Unearned Premiums

Keymed Biosciences (HKSE:02162) Unearned Premiums


View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Unearned Premiums?

Unearned Premiums only applies to insurance companies.


Keymed Biosciences Business Description

Traded in Other Exchanges
Address
No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Executives
Chen Bo 2201 Interest of corporation controlled by you
Eagle Hero Management Limited 2101 Beneficial owner
Trident Trust Company (hk) Limited 2301 Trustee
Moonshot Holdings Limited 2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng